Provention Bio (PRVB) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRVB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVB, but not buy additional shares or sell existing shares.
View PRVB analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price objectives for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $25.00. On average, they expect the company's stock price to reach $22.83 in the next year. This suggests that the stock has a possible downside of 8.6%.
View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts.

Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.07. The business earned $10.81 million during the quarter, compared to analysts' expectations of $7.23 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%.

ETFs with the largest weight of Provention Bio (NASDAQ:PRVB) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ProShares Merger ETF (MRGR), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), IQ Merger Arbitrage ETF (MNA), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sessa Capital IM L.P. (9.37%), BlackRock Inc. (5.98%), State Street Corp (1.83%), Geode Capital Management LLC (1.52%), Water Island Capital LLC (1.01%) and Pictet Asset Management SA (0.81%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP.
View institutional ownership trends.

One share of PRVB stock can currently be purchased for approximately $24.98.

Provention Bio (NASDAQ:PRVB) has a market capitalization of $2.37 billion and generates $12.90 million in revenue each year. The company earns $-113,570,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com.